PubMed Health⌕ Search

PubMed · 2840078

Temperature effects on alpha 2-adrenergic receptor-Gi interactions.

Abstract

The effect of temperature on the binding of alpha 2-adrenergic agonists and antagonists to human platelet membranes was studied. Equilibrium binding of the alpha 2 antagonist, [3H]yohimbine, was affected minimally, whereas the rate of dissociation changed 40-fold over a temperature range of 5-35 degrees. The antagonist dissociation rates were characterized by a linear Arrhenius plot and an activation energy of 20.5 kcal/mol. The equilibrium binding of the full alpha 2 agonist, [3H]UK 14,304 [5-bromo-6-N-2-4,5-dihydroimidazolyl)quinoxaline tartrate] showed a 50% decrease in Bmax at 5 degrees as well as a 2-fold decrease in affinity. The kinetics of [3H]UK 14,304 binding were affected more significantly by decreases in temperature. The agonist exhibited fast and slow phases of binding. The fast binding was minimally sensitive to temperature in the range of 0-30 degrees with only a 6-fold change in rate. The slow binding rates changed nearly 100-fold over the same temperature range. Also, the slow rate of agonist binding was characterized by a nonlinear Arrhenius plot with a "break" at approximately 17 degrees, which was found previously to be the phase transition temperature of platelet membrane lipids [Lohse et al., Molec. Pharmac. 29, 228 (1986)]. Despite the reduction of high affinity [3H]UK 14,304 binding at 5 degrees, approximately half of the binding remained sensitive to guanine nucleotides. The data are interpreted in the context of a model in which the fast agonist binding represents a bimolecular interaction of ligand with two pre-existing conformations of the alpha 2 receptor, one coupled to Gi and the other permanently uncoupled. The slow binding of agonist appears to require protein diffusion in the lipid membrane or a protein conformational change which is dependent on the lipid environment.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R D Gantzos, R R Neubig. 1988-07-15. Temperature effects on alpha 2-adrenergic receptor-Gi interactions.. https://doi.org/10.1016/0006-2952(88)90045-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Prostaglandin E(2) protects human lung fibroblasts from cigarette smoke extract-induced apoptosis via EP(2) receptor activation.

Prostaglandin E(2) (PGE(2)) has been shown to have a strong cytoprotective effect, inhibiting apoptosis. In the present study, we evaluated whether PGE(2) has a protective effect on cigarette smoke extract (CSE)-induced apoptosis in human lung fibroblasts. Apoptosis was assessed by various methods, including DNA content analysis. CSE (15%-20%) led to apoptosis and induced imbalance in favor of pro- over anti-apoptotic protein expression and activated caspases. PGE(2) blocked CSE-induced apoptosis and modulated the balance of pro- and anti-apoptotic proteins and decreased the activation of caspases. This anti-apoptotic effect was mediated via EP(2) receptor activation as the EP(2) agonist butaprost mimicked PGE(2) activity and siRNA for the EP(2) receptor blocked it. An adenylyl cyclase inhibitor was found to abolish the PGE(2)-mediated cytoprotective effect. Correspondingly, c-AMP analogs blocked CSE-induced apoptosis. Consistently, the protein kinase A (PKA) inhibitor KT-5720 abolished PGE(2)-mediated protection. PGE(2) and butaprost phosphorylated Bad and KT-5720 blocked phosphorylation. These results suggest that PGE(2) inhibits CSE-induced apoptosis via EP(2) receptor activation and activation of PKA, which leads to an alteration in the balance between pro- and anti-apoptotic factors. Through such a mechanism, PGE(2) may alter survival of cells in the smoke-exposed lungs, thus affecting the pathogenesis of cigarette smoke-induced disease.

Adenylyl Cyclase Inhibitors↗

Cyclosporine attenuates the adenylyl cyclase superactivation induced by chronic cannabinoid treatment.

Chronic cannabinoid treatment results in the development of tolerance. Adenylyl cyclase superactivation, induced by chronic cannabinoid agonist administration, is regarded as one of the molecular mechanisms leading to tolerance. In the present study, the effect of cyclosporine on adenylyl cyclase superactivation after chronic exposure to WIN 55,212-2, a cannabinoid receptor agonist, was studied. Chronic treatment (18 h) with WIN 55,212-2 induced a significant increase in cAMP levels in human astrocytoma cells (adenylyl cyclase superactivation). Acute treatment with cyclosporine (10 min) did not have any effect on WIN 55,212-2-induced adenylyl cyclase superactivation. But, chronic cyclosporine treatment (18 h), with concentration from 1 nM to 1 microM, attenuates the development of adenylyl cyclase superactivation after chronic WIN 55,212-2 treatment. Our findings show that cyclosporine attenuates chronic cannabinoid-mediated adenylyl cyclase superactivation.

Adenylyl Cyclase Inhibitors↗

The calcium paradoxon of renin release: calcium suppresses renin exocytosis by inhibition of calcium-dependent adenylate cyclases AC5 and AC6.

An increase in the free intracellular calcium concentration promotes exocytosis in most secretory cells. In contrast, renin release from juxtaglomerular (JG) cells is suppressed by calcium. The further downstream signaling cascades of this so called "calcium paradoxon" of renin secretion have been incompletely defined. Because cAMP is the main intracellular stimulator of renin release, we hypothesized that calcium might exert its suppressive effects on renin secretion via the inhibition of the calcium-regulated adenylate cyclases AC5 and AC6. In primary cultures of JG cells, calcium-dependent inhibitors of renin release (angiotensin II, endothelin-1, thapsigargin) suppressed renin secretion, which was paralleled by decreases in intracellular cAMP levels [cAMP]. When [cAMP] was clamped by membrane permeable cAMP derivates, renin release was not suppressed by any of the calcium liberators. Additionally, both endothelin and thapsigargin suppressed cAMP levels and renin release in isoproterenol or forskolin-pretreated As4.1 cells, a renin-producing cell line that expresses AC5 and AC6. The calcium-dependent inhibition of intracellular cAMP levels and renin release was prevented by small interfering RNA-mediated knockdown of AC5 and/or AC6 expression, underlining the functional significance of these AC isoforms in renin-producing cells. Finally, in isolated perfused mouse kidneys, angiotensin II completely inhibited the stimulation of renin secretion induced by adenylate cyclase activation (isoproterenol) but not by membrane permeable cAMP analogs, supporting the conclusion that the suppressive effect of calcium liberators on renin release is mediated by inhibition of adenylate cyclase activity.

Adenylyl Cyclase Inhibitors↗